News

The Biosphere hosts workshop to generate ideas to address unmet clinical needs in children’s cancer care

Despite improving survival rates, cancer is the leading cause of death in children and young people. There is a growing need for technology to support children and young people with cancer, as well as to support health care professionals to provide optimal care.

NIHR Children and Young People MedTech Co-operative (NIHR CYP MedTech) collaborated with the Academic Health Science Network North East and North Cumbria, NIHR Clinical Research Network North East and North Cumbria, MedConnect North, and Lab4Living to deliver an innovation workshop at The Biosphere, Newcastle Helix.

PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director

Cambridge, UK, 15 July 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has appointed Dr Lorenz Mayr to its Board as Non-Executive Director. Dr Mayr’s experience in drug discovery and development, and specifically his expertise in functional genetic screening in target identification, will help drive the expansion of PhoreMost’s next-generation SITESEEKER® target discovery platform and guide the development of the Company’s drug discovery programme.

Wise Owl Competition - Summer Social

Planning to attend the BioWednesday Summer Social on 14 August 2019? Do you fancy winning one of our wise owls? By registering and attending the event, you are automatically entered into the competiton to win one of the below owls!

Dr Neil Thompson Appointed Chief Scientific Officer of Healx to Spearhead Drug Discovery Expansion

• Career that spans biotech and pharma including at Astex Pharmaceuticals and GSK

• Has led discovery of over 10 drugs taken into clinical development, including the two recent drugs from the Astex stable that have received marketing approval

• Will grow in-house drug development team to harness power of AI and take rare disease treatments from prediction through to the clinical stage

BioIVT to Host Webinar on How to Evaluate BSEP Inhibition and Reduce Drug-induced Liver Injury (DILI) Risk during Drug Development

Westbury, NY – July 10, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is hosting a webinar that will present the latest in vitro research methods and International Transporter Consortium (ITC) guidance for assessing bile salt export pump (BSEP) inhibition to reduce and manage the risk of drug-induced liver injury (DILI) during drug development.

Invest Newcastle show off the region’s innovative life science sector to Cuban visitors

Invest Newcastle has welcomed a senior Cuban life science business delegation to the region for a two-day visit. They used this opportunity to show off the city’s life science strengths and world-leading universities.

Extensive CAR-T Cell Range for Research & Immunotherapy

AMSBIO announce new, best-in-class CAR-T cells, engineered CAR-T target cells, PBMC, cell media and activation beads in response to the rapid growth in research on the therapeutic uses of CAR-T cells.

All CAR-T cell products from AMSBIO are T cells produced from either a group of donors or from individual donor transduced with CAR (Chimeric antigen receptor) - lentivirus.

Catalent Extends Global Commercial Spray Drying Capabilities in Europe

SOMERSET, N.J. – July 9, 2019 — Catalent, Inc.

Sunil Shah, o2h Ventures wins Angel Investor of the Year

Cambridge, UK, 4th July, 2019: We are delighted to announce Sunil Shah, CEO, o2h Ventures, has won the prestigious UKBAA Angel Investor of the Year Award for his active participation in backing high growth potential startups and early-stage businesses in the UK. Sunil’s contribution has been instrumental in the growth of biotech in UK. He has been investing into the biotech therapeutics sector since many years – a sector from which traditionally many angel investors have stayed away.

Arecor Signs A New Formulation Evaluation Agreement With An Existing Partner, A Major Global Pharmaceutical Company

Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.

My Account